Clinical Trial: Alternating Triamcinolone and Platelet-Rich Plasma Therapy for Oral Submucous Fibrosis

U.S., Dec. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07277998) titled 'Alternating Triamcinolone and Platelet-Rich Plasma Therapy for Oral Submucous Fibrosis' on Nov. 27.

Brief Summary: Oral Submucous Fibrosis (OSF) is a chronic, progressive, potentially malignant disorder characterized by mucosal stiffness, trismus, and burning sensation. This interventional clinical trial evaluates the therapeutic effectiveness of alternating weekly intralesional Triamcinolone Acetonide (TA) and Platelet-Rich Plasma (PRP) injections compared to standard Triamcinolone therapy alone. The purpose is to determine whether sequential anti-inflammatory (TA) and regenerative (PRP) stimulation can produce superior clinical im...